Ionis Pharmaceuticals, Inc.

797 articles with Ionis Pharmaceuticals, Inc.

• 

  Clinical Catch-Up: August 31-September 4

  9/8/2020

  It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.

• Ionis to present at upcoming virtual investor conferences - Sep 03, 2020

  9/3/2020

  Ionis Pharmaceuticals, Inc., the leader in antisense therapeutics, announced that management will present a company overview at the following virtual investor conferences

• New England Journal of Medicine publishes study results evaluating Ionis antisense therapy in treatment of patients with hereditary angioedema

  9/2/2020

  Compassionate-use study supports continued development of IONIS-PKK-LRx as an experimental treatment to reduce acute attacks of hereditary angioedema

• Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics

  8/31/2020

  Ionis to acquire remaining 24% of common stock of Akcea it does not already own for $18.15 per share in cash

• 

  Akcea Skyrockets Following Ionis' Acquisition of All Outstanding Shares

  8/31/2020

  Shares of Akcea Therapeutics were up more than 58% in premarket trading after its majority owner Ionis Pharmaceuticals announced it will acquire all outstanding shares of the company, which amounts to about 24% of available stock for $18.50 per share.

• Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020

  8/29/2020

  Results from Phase 2 study demonstrate patients receiving vupanorsen experienced significant, dose-dependent reductions in triglyceride levels, ANGPTL3 and additional lipid parameters compared to placebo

• Ionis Pharmaceuticals to hold cardio-renal franchise webcast

  8/26/2020

  Ionis Pharmaceuticals, Inc. announced that it will host a live webcast on Wednesday, September 2nd at 10:00 a.m. Eastern Time to review its cardio-renal franchise.

• Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020

  8/24/2020

  Late-breaking presentation to focus on efficacy and safety data of vupanorsen in patients with hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty liver disease

• Ionis reports second quarter 2020 financial results and recent business achievements

  8/5/2020

  Ionis Pharmaceuticals, Inc. reported its financial results for the second quarter of 2020 and recent business highlights.

• Ionis Pharmaceuticals to hold second quarter 2020 financial results webcast

  7/22/2020

  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, August 5 th at 11:30 a.m. Eastern Time to discuss its second quarter 2020 financial results and report on pipeline and busines

• Akcea Appoints New Senior Vice President, Global Medical Affairs

  7/20/2020

  Dr. Christophe Hotermans joins company, with a decade of clinical practice and 12 years of experience in global biotechnology sector.

• Ionis Pharmaceuticals to hold neurology franchise webcast

  7/7/2020

  Ionis Pharmaceuticals, Inc. announced that it will host a live webcast on Tuesday, July 14th at 10:00 a.m. Eastern Time to review its neurology franchise.

• Ionis Pharmaceuticals to present at upcoming virtual investor conferences - June 05, 2020

  6/5/2020

  Ionis Pharmaceuticals, Inc., the leader in antisense therapeutics, announced that management will present a company overview at the following virtual investor conferences

• Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Portugal for treatment of hereditary transthyretin amyloidosis with polyneuropathy

  6/1/2020

  Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced the Portuguese Medicine Regulatory Authority has granted approval for reimbursement of TEGSEDI® for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis.

• Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy

  5/14/2020

  Akcea Therapeutics, Inc. announced The Ministry of Health of Spain has granted approval for the reimbursement of TEGSEDI® in the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis.

• Akcea Expands Leadership Team with Appointment of Carla Poulson as Senior Vice President and Chief Human Resources Officer

  5/7/2020

  Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced that Carla Poulson has joined the company as senior vice president and chief human resources officer.

• Ionis reports first quarter 2020 financial results and recent business achievements

  5/6/2020

  Ionis Pharmaceuticals, Inc. reported its financial results for the first quarter of 2020 and recent business highlights.

• Akcea Reports Financial Results and Highlights for First Quarter 2020

  5/5/2020

  Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing medicines to treat patients with serious and rare diseases, reported financial results for the first quarter ended March 31, 2020.

• Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders

  5/1/2020

  Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2020 Virtual Annual Meeting of Stockholders and provide a general corporate update on Thursday, June 4, 2020 . In consideration of the health and well-being of our stockholders, directors and employees, and in compliance with federal,

• Ionis Pharmaceuticals to hold first quarter 2020 financial results webcast

  4/22/2020

  Webcast scheduled for Wednesday, May 6 at 11:30 a.m. Eastern Time